BN201

BN201 is a first-in-class small peptide molecule and neuroprotective agent developed for the treatment of neurodegenerative diseases. It acts as a selective agonist of serum/glucocorticoid-regulated kinase 2 (SGK2), promoting remyelination and neuroprotection. Mechanistically, BN201 stimulates the differentiation of oligodendrocyte precursor cells into mature oligodendrocytes and enhances myelin sheath formation around axons. It also modulates several kinases in the insulin growth factor 1 pathway—including SGK and midkine—induces phosphorylation of NDRG1, and causes cytoplasmic translocation of Foxo3. In preclinical models, it prevents axonal/neuronal loss and promotes remyelination in multiple sclerosis (MS), chemically induced demyelination, glaucoma, and acute optic neuritis (AON). The drug has demonstrated blood-brain barrier penetration in animal studies. Bionure is developing BN201 primarily for MS, AON (for which it received FDA orphan designation), neuromyelitis optica (NMO), and glaucoma[4][5][6][8][10].

Other names

Glycinamide n-(2-(2-fluorophenyl)ethyl)glycyl-n-(2-methylpropyl)glycyl-n2-(3-(2-oxo-1-pyrrolidinyl)propyl)N-(2-amino-2-oxoethyl)-2-(2-((4-fluorophenethyl)amino)-N-isobutylacetamido)-N-(3-(2-oxopyrrolidin-1-yl)propyl)acetamideN-({Carbamoylmethyl-[3-(2-oxo-pyrrolidin-1-yl)propyl}-carbamoyl}-methyl)-2-[2-(2-fluorophenyl)-ethylamino]-N-isobutyl-acetamide